spacer
home > ict > spring 2008 > materialising markets
PUBLICATIONS
International Clinical Trials

Materialising Markets

Jerry Boxall of ACM-Pivotal Europe explores the pros and cons of clinical research in the emerging markets from the point of view of a global clinical trials organisation

As the global market continues to expand, pharmaceutical companies must make decisions about which of the key emerging regions to focus on when it comes to clinical trials. Expansion into new markets is nothing new for the pharmaceutical industry, and within Europe we have seen the countries of Central and Eastern Europe (CEE) emerge as major centres for clinical research over the past decade. As with every new opportunity, there are risks associated with conducting research in emerging regions, and a look back at the lessons learnt from the CEE region may be a valuable exercise in identifying potential threats in new locations across the globe.

There is no doubt that momentum is gathering in favour of the emerging economies. According to the Financial Times, the proportion of principal investigators registered with the US Food and Drug Administration – but based outside the US and Western Europe – rose from five per cent in 1997 to 29 per cent last year, with the fastest growth coming from India, China, Russia and Argentina in the past five years (1). These regions are prime clinical trial locations; they offer low cost services, skilled investigators, and a large, diverse pool of highly compliant patients.

Companies that have already explored the opportunities in these new locations have increased patient recruitment by 20 to 30 per cent, whilst also reducing costs. In Phase III trials, research shows that it is common for results to come in six or seven months quicker than in domestic markets – all elements that help to get the drug to market and generate revenue more quickly. However, the globalisation of clinical trials has faced increasing scrutiny over issues such as the quality of data, ethical considerations and the safety of the patients involved.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jerry Boxall is a Member of the Institute of Clinical Research (ICR) and is Managing Director, Europe, of ACM-Pivotal. Trained as a Biomedical Scientist, Jerry has over 25 years’ experience in this field. For the past 15 years he has held senior central laboratory posts both in the UK and Europe. Jerry has been heavily involved in the establishment of both European and global central laboratories in Germany, France, Denmark, the Netherlands and the UK. Jerry joined the ACM-Pivotal team from CRL-Medinet in June 2000 as Head of European Operations, and took over as Managing Director, Europe, in January 2005
spacer
Jerry Boxall
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT Offers First Patient-Administered ECG Assessment for Continuation of Clinical Trials during COVID-19

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a first-of-its-kind partnership with AliveCor, the leader in AI-based, personal ECG technology. The partnership enables ERT to capture digital cardiac safety data with KardiaMobile 6L, the only FDA-cleared personal ECG for patient-administered 6-lead data collection.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement